NEW YORK (GenomeWeb) – OneOme and Rainbow Genomics today announced a deal to provide OneOme's RightMed pharmacogenomic test with Rainbow Genomics' whole-exome sequencing test services to patients in Hong Kong, Japan, and Macau.
The full OneOme RightMed platform will be offered by Rainbow to patients and physicians, the firms added.
Financial and other terms of the deal were not disclosed.
According to Rainbow CEO Daniel Siu, patients in Hong Kong, Japan, and Macau are increasingly taking medications developed by US and European drug firms, which have limited dosing and side effect information based on Asian genetics. The result is that patients "suffer from imprecise medication and treatment due to outdated trial-and-error techniques," he said in a statement. The deal with OneOme "offers a highly credible [pharmacogenomic] solution with clinical utility appropriate for Asian patients to guide physicians and personalize medicine," Siu added.
Rainbow has operations in Hong Kong, Japan, and the US and focuses on whole-exome sequencing and pharmacogenomic tests for diagnostic, treatment, and disease prevention applications.